MS Franchise A Surprising Concern For Sanofi In Q3; Dupixent Out-Performs
Sanofi produced a mixed financial performance in the third quarter of 2017, with reported sales more than €200m below analysts' expectations but new drug Dupixent doing well; MS drug sales have fallen since Q2 by more than €50m.
You may also be interested in...
Swiss major Roche has finally got a positive opinion for its closely watched drug but concerns have been raised that Ocrevus will only be licensed for early-stage primary progressive multiple sclerosis patients.
The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.